Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity
Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples per year.
“These additional resources will support our recently launched commercial services which, for the first time, will provide the pharmaceutical and biobanking industries with access to our proprietary metabolic database, as well as to our advanced interpretive software to assist in various phases of drug research, development, and manufacturing,” said Dr. Ali Tinazli, CEO of Lifespin GmbH.
Achieving Speed, Cost-Effectiveness, and Scalability
Because Lifespin’s instrument systems are fully automated, operate 24/7, and require very little maintenance and offline times, its services are highly automated, scalable, and cost-effective for multiparameter quantification in biofluids.
“Our business model is driven by an understanding that scalable infrastructures, like those we have and are developing, are an indispensable prerequisite to foster clinical accessibility, affordability, and market penetration of precision medicine tools,” said Dr. Roland Geyer, Lifespin’s Chief Operating Officer.
“With additional analytical lines, Lifespin will be able to accelerate the clinical availability of our database to prospective partners, and digitize large clinical cohorts, without limiting our extraordinary turnaround times and services.”
Lifespin is working to build new precision medicine tools based on quantitative metabolic profiles and proprietary algorithms to assist in the early detection of diseases and monitoring the efficacy of health treatments.
To facilitate these services, the company has established one of the largest and most comprehensive databases of metabolic health profiles across healthy and diseased individuals covering multiple age and gender groups as well as specific diseases in neurology, oncology, and inflammation.